89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibrob…
Biotechnology
US, San Francisco [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about 89bio, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2022 | -4.4800 | -3.041 | 0 | 1 | -90 | -216 | -90 | 0 | -89 | 0 | 19 | 0 |
| 2023 | -2.9300 | -2.033 | 0 | 0.27 | -102 | -153 | -99 | 0 | -102 | 0 | 21 | 0 |
| 2024 | -2.0000 | -3.177 | 0 | 1 | -142 | -227 | -134 | 0 | -151 | 0 | 28 | 0 |
| 2025 | - | -2.932 | - | 2 | - | -215 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2027 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2028 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |